The importance of quality of life in patients with alcohol abuse and dependence

Harvard Review of Psychiatry

Volumn 21, Issue 1, 2013, Pages 1-17

  Ugochukwu, Chio ^a   Bagot, Kara Simone ^c   Delaloye, Sibylle ^a   Pi, Sarah ^a   Vien, Linda ^a   Garvey, Tim ^a   Bolotaulo, Nestor Ian ^a   Kumar, Nishant ^a   Ishak, Waguih William ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol abuse; Alcohol dependence; Alcohol abuse measures; Alcohol use disorders; Healthrelated quality of life; Quality of life

Indexed keywords

ACAMPROSATE; DISULFIRAM; NALTREXONE; TOPIRAMATE;

ADDICTION SEVERITY INDEX; ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOLISM; DETOXIFICATION; HUMAN; LIFE SATISFACTION; MENTAL FUNCTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REVIEW; SOCIAL INTERACTION; VALIDITY;

ALCOHOLISM; ATTITUDE TO HEALTH; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HEALTH STATUS; HUMANS; INTERPERSONAL RELATIONS; PERSONAL SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SELF EFFICACY;

EID: 84876366335     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0b013e31827fd8aa     Document Type: Review

References (94)

1. World Health Organization. Constitution of the World Health Organization. Preamble. http://www.who.int/governance/eb/who-constitution-en.pdf.
2. World Health Organization, Division of Mental Health and Prevention of Substance Abuse.WHOQOL: measuring quality of life. Geneva: WHO, 1997.
3. The Netherlands Cancer Institute, Amsterdam. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002;11:193-205.
4. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;272:619-26.
5. Goh CR, Lee KS, Tan TC, et al. Measuring quality of life in different cultures: translation of the Functional Living Index for Cancer (FLIC) into Chinese and Malay in Singapore. Ann Acad Med Singapore 1996;25:323-34.
6. Murray CJL, Lopez AD. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press, 1996.
7. Lasalvia A, Ruggeri M, Santolini N. Subjective quality of life: its relationship with clinician-rated and patient-rated psychopathology. The South-Verona Outcome Project 6. Psychother Psychoso 2002;71:275-84.
8. IsHak WW, Greenberg JM, Balayan K, et al. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry 2011;19:229-39.
9. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse/dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007;64:830-42.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Press, 2000.
11. Laudet AB, Becker JB, White WL. Don't wanna go through that madness no more: quality of life satisfaction as predictor of sustained remission from illicit drug misuse. Subst Use Misuse 2009;44:227-52.
12. Donovan D, Mattson ME, Cisler RA, Longabaugh R, Zweben A. Quality of life as an outcome measure in alcoholism treatment research. J Stud Alcohol 2005;15(suppl):119-39.
13. Miller PG, Miller WR. What should we be aiming for in the treatment of addiction? Addiction 2009;104:685-6.
14. Foster JH, Powell JE, Marshall EJ, Peters TJ. Quality of life in alcohol-dependent subjectsVa review. Qual Life Res 1999; 8:255-61.
15. Longabaugh R, Mattson ME, Connors GJ, Cooney NL. Quality of life as an outcome variable in alcoholism treatment research. J Stud Alcohol Suppl 1994;12:119-29.
16. Babor TF, Longabaugh R, Zweben A, et al. Issues in the definition and measurement of drinking outcomes in alcoholismtreatment research. J Stud Alcohol Suppl 1994;12:101-11.
17. Finney JW, Moyer A, Swearingen CE. Outcome variables and their assessment in alcohol treatment studies: 1968Y1998. Alcohol Clin Exp Res 2003;27:1671-9.
18. Muldoon MF, Barger SD, Flory JD, Manuck SB. What are quality of life measurements measuring? BMJ 1998;316:542-5.
19. Guyatt GH. A taxonomy of health status instruments. J Rheumatol 1995;22:1188-90.
20. Costenbader EC, ZuleWA, Coomes CM. The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for hepatitis C infection. Drug Alcohol Depend 2007;89:251-8.
21. Daeppen JB, Krieg MA, Burnand B, Yersin B. MOS-SF-36 in evaluating health-related quality of life in alcohol-dependent patients. Am J Drug Alcohol Abuse 1998;24:685-94.
22. Feeney GF, Connor JP, Young RM, Tucker J, McPherson A. Alcohol dependence: the impact of cognitive behaviour therapy with or without naltrexone on subjective health status. Aust N Z J Psychiatry 2004;38:842-8.
23. Kiritze-Topor P, Huas D, Rosenzweig C, Comte S, Paille F, Lehert P. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care. Alcohol Alcohol 2004;39: 520-7.
24. Lahmek P, Berlin I, Michel L, Berghout C, Meunier N, Aubin HJ. Determinants of improvement in quality of life of alcohol-dependent patients during an inpatient withdrawal programme. Int J Med Sci 2009;6:160-7.
25. LoCastro JS, Youngblood M, Cisler RA, et al. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs 2009;70: 186-96.
26. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003;12: 1061-7.
27. Morgan MY, Landron F, Lehert P. Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support. Alcohol Clin Exp Res 2004;28: 64-77.
28. Morgan TJ, Morgenstern J, Blanchard KA, Labouvie E, Bux DA. Health-related quality of life for adults participating in outpatient substance abuse treatment. Am J Addict 2003; 12:198-210.
29. Panagaria N, Varma K, Nijhawan S, Mathur A, Rai RR. Quality of life and nutritional status in alcohol addicts and patients with chronic liver disease. Trop Gastroenterol 2007; 28:171-5.
30. Patience D, Buxton M, Chick J, Howlett H. The SECCATT Survey: II. The alcohol related problems scale as a proxy for resource costs and quality of life in alcoholism treatment. Alcohol Alcohol 1997;32:79-84.
31. Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, OMalley SS. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res 2009;33:350-6.
32. Senbanjo R, Wolff K, Marshall J. Excessive alcohol consumption is associated with reduced quality of life among methadone patients. Addiction 2007;102:257-63.
33. Romeis JC, Waterman B, Scherrer JF, et al. The impact of sociodemographics, comorbidity and symptom recency on health-related quality of life in alcoholics. J Stud Alcohol 1999;60:653-62.
34. Volk RJ, Cantor SB, Steinbauer JR, Cass AR. Alcohol use disorders, consumption patterns, and health-related quality of life of primary care patients. Alcohol Clin Exp Res 1997;21: 899-905.
35. Walters D, Connor JP, Feeney GF, Young RM. The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence. J Addict Dis 2009;28:137-44.
36. Mutebi A, Brazier JE, Walters SJ. A comparison of the discriminative and evaluative properties of the SF-36 and the SF-6D index. Qual Life Res 2011;20:1477-86.
37. McKenna M, Chick J, Buxton M, Howlett H, Patience D, Ritson B. The SECCAT survey: I. The costs and consequences of alcoholism. Alcohol Alcohol 1996;31:565-76.
38. Gunther O, Roick C, Angermeyer MC, Konig HH. The EQ- 5D in alcohol dependent patients: relationships among healthrelated quality of life, psychopathology and social functioning. Drug Alcohol Depend 2007;86:253Y64.
39. Gunther OH, Roick C, Angermeyer MC, Konig HH. Responsiveness of EQ-5D utility indices in alcohol-dependent patients. Drug Alcohol Depend 2008;92:291Y5.
40. Saatcioglu O, Yapici A, Cakmak D. Quality of life, depression and anxiety in alcohol dependence. Drug Alcohol Rev 2008;27:83-90.
41. Johnson BA, Rosenthal N, Capece JA, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 2008;168:1188-99.
42. Mas-Exposito L, Amador-Campos JA, Gomez-Benito J, Lalucat-Jo L. The World Health Organization Quality of Life Scale Brief Version: A validation study in patients with schizophrenia. Qual Life Res 2011;20:1079-89.
43. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 1993;29:321-6.
44. Florez G, Garcia-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res 2008;32: 1251-9.
45. Florez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res 2011;17:29-36.
46. Foster JH, Peters TJ, Kind P. Quality of life, sleep, mood and alcohol consumption: A complex interaction. Addict Biol 2002; 7:55-65.
47. Laaksonen E, Koski-Jannes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2008;43:53-61.
48. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-D-5L). Qual Life Res 2011;20:1727-36.
49. Foster JH, Marshall EJ, Peters TJ. Application of a quality of life measure, the life situation survey (LSS), to alcoholdependent subjects in relapse and remission. Alcohol Clin Exp Res 2000a;24:1687-92.
50. Foster JH, Peters TJ, Marshall EJ. Quality of life measures and outcome in alcohol-dependent men and women. Alcohol 2000b;22:45-52.
51. Andreasson S, Hansagi H, Osterlund B. Short-term treatment for alcohol-related problems: four-session guided self-change versus one session of adviceVa randomized, controlled trial. Alcohol 2002;28:57-62.
52. Foster JH, Peters TJ. Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome. Alcohol Clin Exp Res 1999;23:1044-51.
53. San Jose B, van de Mheen H, van Oers JA, Mackenach JP, Garretsen HF. The U-shaped curve: various health measures and alcohol drinking patterns. J Stud Alcohol 1999;60: 725-31.
54. Hunt S, McKenna SP, McEwen J, Backett E, Williams J, Papp E. A quantitative approach to perceived health status: A validation study. J Epidemiol Community Health 1980;34:281-6.
55. Anderson RT, Aaronson NK, Bullinger M, McBee WL. A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research. Pharmacoeconomics 1996;10:336-55.
56. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000;17:13-35.
57. Malet L, Llorca PM, Beringuier B, Lehert P, Falissard B. AlQoL 9 for measuring quality of life in alcohol dependence. Alcohol Alcohol 2006;41:181-7.
58. Drummond D.C. The relationship between alcohol dependence and alcohol-related problems in a clinical population. Br J Addict 1990;85:357-66.
59. Edwards G, Chandler J, Hensman C, Peto J. Drinking in a London suburb. Correlates of troubles with drinking among men. Q J Stud Alcohol 1972;suppl 6:94-119.
60. Wanberg KW, Horn JL. Assessment of alcohol use with multidimensional concepts and measures. Am Psychol 1983;38: 1055-69.
61. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992;9: 199-213.
62. Carise D, McLellan AT, Cacciola J, et al. Suggested specifications for a standardized Addiction Severity Index database. J Subst Abuse Treat 2001;20:239-44.
63. Wertz JS, Cleaveland BL, Stephens RS. Problems in the application of the Addiction Severity Index (ASI) in rural substance abuse services. J Subst Abuse 1995;7:175-88.
64. Kokkevi A, Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Euro Addict Res 1995;1:208-10.
65. Cacciola JS, Alterman AI, McLellan AT, Lin Y, Lynch KG. Initial evidence for the reliability and validity of a Blite[ version of the Addiction Severity Index. Drug Alcohol Depend 2007;87:297-302.
66. Makela K. Studies of the reliability and validity of the Addiction Severity Index. Addiction 2004;99:398-410.
67. Pelc I, Ansoms C, Lehert P, et al. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol Clin Exp Res 2002;26:1529-38.
68. Clark DB, Kirisci L. Posttraumatic stress disorder, depression, alcohol use disorders and quality of life in adolescents. Anxiety 1996;2:226-33.
69. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: A randomized controlled trial. Arch Gen Psychiatry 2004;61:905-12.
70. Hayashida M. An overview of outpatient and inpatient detoxification. Alcohol Health Res World 1998;22:44-6.
71. Al-Sanouri I, Dikin M, Soubani AO. Critical care aspects of alcohol abuse. South Med J 2005;98:372-81.
72. Berglund M, Thelander S, Jonsson E. Treating alcohol abuse and drug abuse: an evidence based review. Weinheim, Germany: Wiley-VCH, 2003.
73. Soyka M, Kranzler HR, Berglund M, et al; WFSBP Task Force on Treatment Guidelines for Substance Use Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part I: alcoholism. World J Biol Psychiatry 2008; 9:6-23.
74. Harris BR, Prendergast MA, Gibson DA, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002;26:1779-93.
75. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000; 35:176-87.
76. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010a;(9):CD004332.
77. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004;28:51-63.
78. Pelc I, Verbanck P, LeBon O, Gavnovlic M, Lion K, Lehert P. Efficacy and safety of acmprosate in the treatment of detoxified alcohol-dependent patients. Br J Psychiatry 1997;170:73-7.
79. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate: results from a placebo controlled study in alcohol dependence. Arch Gen Psychiatry 1996;53: 673-80.
80. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-42.
81. Krampe H, Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 2010;16:2076-90.
82. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010b;(12): CD001867.
83. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 2009;36: S15-23.
84. Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 2010;16:2103-12.
85. Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry 2011;11:41.
86. Soyka M, Rosner S. Emerging drugs to treat alcoholism. Expert Opin Emerg Drugs 2010;15:695-711.
87. Harm Reduction Coalition. Principles of harm reduction. n.d. http://harmreduction.org/about-us/principles-of-harm-reduction/.
88. Acil AA, Dogan S, Dogan O. The effects of physical exercises to mental state and quality of life in patients with schizophrenia. J Psychiatr Ment Health Nurs 2008;15:808-15.
89. Larun L, Nordheim LV, Ekeland E, Hagen KB, Heian F. Exercise in prevention and treatment of anxiety and depression among children and young people. Cochrane Database Syst Rev 2006;19(3):CD004691.
90. Nyklíček I, Kuijpers KF. Effects of mindfulness-based stress reduction intervention on psychological well-being and quality of life: is increased mindfulness indeed the mechanism? Ann Behav Med 2008;35:331-40.
91. Hamre HJ, Witt CM, Glockmann A, Ziegler R, Willich SN, Kiene H. Rhythmical massage therapy in chronic disease: A 4-yearprospective cohort study. J Altern Complement Med 2007;13:635-42.
92. Marziali E, McDonald L, Donahue P. The role of coping humor in the physical and mental health of older adults. Aging Ment Health 2008;12:713Y8.
93. Vilhauer JS, Young S, Kealoha C, et al. Treating major depression by creating positive expectations for the future: A pilot study for the effectiveness of future-directed therapy (FDT) on symptom severity and quality of life. CNS Neurosci Ther 2012;18:102-9.
94. Van der Watt G, Laugharne J, Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr Opin Psychiatry 2008;21:37-42.